Cardiovascular adverse events in patients with non-Hodgkin lymphoma treated with first-line cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP with rituximab (R-CHOP): a systematic review and meta-analysis
Review of 137 studies (n=21,211) notes increase in heart failure rates, indicating that this complication remains undiagnosed in patients with non-Hodgkin lymphoma who received first-line R-CHOP or CHOP, and stresses the need for cardiac monitoring during and after chemotherapy.
Source:
The Lancet Haematology
SPS commentary:
A related editorial discusses this review, highlighting the recommendation to carry out cardiac monitoring goes against American Society of Clinical Oncology guidelines, and European Society for Medical Oncology recommendations. However, cardiac assessment, including echocardiography, should be regarded as necessary for all asymptomatic patients within 6–12 months of completing an anthracycline-containing regimen, as most episodes of cardiotoxicity occur during this period.